SUBSTRATA MAIN PAGE


Oscillibacter

RANK: Genus

TAXONOMY: Bacteria -> Terrabacteria group -> Firmicutes -> Clostridia -> Clostridiales -> Oscillospiraceae -> Oscillibacter

OVERVIEW:

Cells are irregular rods (0.5 × 1.0–2.0 µm). Gram-stain-positive, not acid-fast. Endospores are not formed. Nonmotile. Aerobic to anaerobic. Good growth on complex organic media at 28–30°C. NaCl in the culture medium may be tolerated up to 10%. Oxidase-negative, catalase-positive. The peptidoglycan type is A4α with an l-Ser residue at position 1 of the peptide subunit. The acyl type is acetyl. The major cell wall sugar is galactose. The predominant menaquinone is MK-8(H4). The major polar lipids consist of phosphatidylethanolamine and phosphatidylglycerol. The cellular fatty acid profile is dominated by the occurrence of iso- and anteiso-branched-chain acids. Mycolic acids are absent. Based on 16S rRNA gene sequence similarities, the genus is closely related to other genera of the family Beutenbergiaceae (95.1–96.3%).The genus Oscillibacter has been known since 2007, but no association to human infection has been reported. Here, we present four cases of Oscillibacter ruminantium bacteremia from hospitals across Denmark from 2001 to 2010. Correct identification is now possible, as the 16S rRNA gene sequence was recently made publicly available.[ PMID: 24501034 ]Participants with asymptomatic atherosclerosis did not exhibit an obvious change in gut microbiota and blood TMAO levels; however, stroke and transient ischemic attack patients showed significant dysbiosis of the gut microbiota, and their blood TMAO levels were decreased. Stroke and transient ischemic attack patients had more opportunistic pathogens, such as Enterobacter, Megasphaera, Oscillibacter, and Desulfovibrio, and fewer commensal or beneficial genera including Bacteroides, Prevotella, and Faecalibacterium. This dysbiosis was correlated with the severity of the disease. The TMAO level in the stroke and transient ischemic attack patients was significantly lower, rather than higher, than that of the asymptomatic group. [PMID: 26597155]

This genus contains microbial species that can reside in the human gastrointestinal tract. [PMC 4262072]



Microbial Abundance Data: Oscillibacter
(Percent of total population with standard deviation [PMID: 22698087])
Group 1
Group 2
Group 3
Group 4
Group 1 Avg
Buccal
Mucosa
Keratinized
Gingiva
Hard
Palate
Group 2 Avg
Throat
Throat
Tonsils
Saliva
Group 3 Avg
Supragingival
Plaque
Subgingival
Plaque
Stool
0.005 %
(0.025)
0.003 %
(0.012)
0.002 %
(0.017)
0.011 %
(0.046)
0.006 %
(0.040)
0.016 %
(0.104)
0.003 %
(0.017)
0.001 %
(0.003)
0.005 %
(0.034)
0.002 %
(0.023)
0.000 %
(0.002)
0.005 %
(0.044)
2.176 %
(2.490)
TAGS
Keystone
Core species
Type species
Pathogen
Dysbiosis associated
Flora/ commensal
Gut associated
Probiotic
Leanness
Obesity
Skin microbiome
Fecal distribution
Oral microbiome
Vaginal microbiome
Butyrate producer
Catalase producer
Histamine producer
Food fermenter
Amylolytic
Propionate producer
Nitrifying
Biofilm producer
DESCENDANTS
INTERACTIONS
KEGG PATHWAYS
  • 2-Oxocarboxylic acid metabolism
  • ABC transporters
  • Alanine, aspartate and glutamate metabolism
  • Amino sugar and nucleotide sugar metabolism
  • Aminoacyl-tRNA biosynthesis
  • Arachidonic acid metabolism
  • Arginine and proline metabolism
  • Arginine biosynthesis
  • Ascorbate and aldarate metabolism
  • Bacterial chemotaxis
  • Bacterial secretion system
  • Base excision repair
  • Benzoate degradation
  • Biosynthesis of amino acids
  • Biosynthesis of antibiotics
  • Biosynthesis of secondary metabolites
  • Biosynthesis of unsaturated fatty acids
  • Biotin metabolism
  • Butanoate metabolism
  • C5-Branched dibasic acid metabolism
  • Carbapenem biosynthesis
  • Carbon metabolism
  • Cationic antimicrobial peptide (CAMP) resistance
  • Chloroalkane and chloroalkene degradation
  • Citrate cycle (TCA cycle)
  • Cyanoamino acid metabolism
  • Cysteine and methionine metabolism
  • D-Alanine metabolism
  • D-Glutamine and D-glutamate metabolism
  • DNA replication
  • Degradation of aromatic compounds
  • Fatty acid biosynthesis
  • Fatty acid degradation
  • Fatty acid metabolism
  • Flagellar assembly
  • Folate biosynthesis
  • Fructose and mannose metabolism
  • Galactose metabolism
  • Glutathione metabolism
  • Glycerolipid metabolism
  • Glycerophospholipid metabolism
  • Glycine, serine and threonine metabolism
  • Glycolysis / Gluconeogenesis
  • Glyoxylate and dicarboxylate metabolism
  • Histidine metabolism
  • Homologous recombination
  • Lysine biosynthesis
  • Lysine degradation
  • Metabolic pathways
  • Methane metabolism
  • Microbial metabolism in diverse environments
  • Mismatch repair
  • Monobactam biosynthesis
  • Naphthalene degradation
  • Nicotinate and nicotinamide metabolism
  • Nitrogen metabolism
  • Nitrotoluene degradation
  • Nonribosomal peptide structures
  • Novobiocin biosynthesis
  • Nucleotide excision repair
  • One carbon pool by folate
  • Oxidative phosphorylation
  • Pantothenate and CoA biosynthesis
  • Pentose and glucuronate interconversions
  • Pentose phosphate pathway
  • Peptidoglycan biosynthesis
  • Phenylalanine metabolism
  • Phenylalanine, tyrosine and tryptophan biosynthesis
  • Phosphonate and phosphinate metabolism
  • Porphyrin and chlorophyll metabolism
  • Propanoate metabolism
  • Protein export
  • Purine metabolism
  • Pyrimidine metabolism
  • Pyruvate metabolism
  • RNA degradation
  • RNA polymerase
  • Riboflavin metabolism
  • Ribosome
  • Secondary bile acid biosynthesis
  • Selenocompound metabolism
  • Starch and sucrose metabolism
  • Streptomycin biosynthesis
  • Styrene degradation
  • Sulfur metabolism
  • Sulfur relay system
  • Synthesis and degradation of ketone bodies
  • Taurine and hypotaurine metabolism
  • Terpenoid backbone biosynthesis
  • Thiamine metabolism
  • Two-component system
  • Tyrosine metabolism
  • Valine, leucine and isoleucine biosynthesis
  • Valine, leucine and isoleucine degradation
  • Vancomycin resistance
  • Vitamin B6 metabolism
  • beta-Alanine metabolism
  • beta-Lactam resistance

  • CLUSTERS WITH
    METABOLOMICS       
    NUTRIENTS/ SUBSTRATES

    ENDPRODUCTS

    INHIBITED BY

    ENHANCED BY
  • Resistant starch (type III)
  • Resistant starch (type II)
  • Resistant starch (type I)

  • BIOTRANSFORMS
  • Ginsenoside Rb1

  • BIOTRANFORM
    ANTIBIOTIC RESISTANCE   
    BIOFILM FORMERS   
    COGEM PATHOGENICITY   

    SUBSTRATA™ IS A REGISTERED TRADEMARK ® OF DATAPUNK BIOINFORMATICS, LLC. COPYRIGHT © 2015, 2016, 2017, 2018 ALL RIGHTS RESERVED.    |    DEVELOPER BLOG     |